12,372 trials
Cardiovascular Diseases · Statin Adverse Reaction
Primary: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) — 819; 927 Participants — p=0.004
Functional Bowel Disorder
Primary: Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores After 4 Weeks of Treatment. — -7.23; -6.48; -5.86 score on a scale — p=0.0042
Eosinophilic Duodenitis · Eosinophilic Gastroenteritis
Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 38; 2 Participants — p=<0.0001
Efficacy and Safety
Primary: Efficacy in Terms of Clinical Status Following Treatment With Pruxelutamide (GT0918) Compared to Placebo — 361; 357 Participants
Eosinophilic Gastritis · Eosinophilic Duodenitis
Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 77; 4 Participants — p=<0.0001
Eosinophilic Esophagitis
Primary: Proportion of Subjects Who Achieve a Peak Esophageal Intraepithelial Count of ≤6 Eosinophils/Hpf at Week 24 — 86; 80; 10 Participants — p=<0.0001
Congenital Bleeding Disorder · Haemophilia B
Primary: Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days) — 2; 0 Participants
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Days Without Daytime or Nighttime Heartburn — 27.7; 44.8; 44.4 Percentage of days — p=<0.0001
Dry Eye Disease (DED)
Primary: Number of Participants With Ocular and Non-ocular Adverse Events — 69; 14; 1; 9 Participants
Beta-Thalassemia
Primary: Percentage of Participants Who Have Achieved Transfusion Independence (TI) — 88.9 Percentage of participants
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set — 8.6; 6.3 Months — p=0.0001
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
Geographic Atrophy · Macular Degeneration
Primary: The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 — 0.336; 0.392…
Angioedema
Primary: Number of Investigator-Confirmed Angioedema Attacks During the Treatment Period of Day 0 Through Day 182 — 1.63; 2.17 attacks/month — p==0.899
Healthy · Type 2 Diabetes
Primary: Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39 — 7.4; 7.9; 7.8; 10.2 pmol/l